Lung Cancer Management最新文献

The association between blood-based HYAL2 methylation and early-stage lung cancer: a case-control study.

IF 0.9

Lung Cancer Management Pub Date : 2025-12-01 Epub Date: 2025-04-01 DOI: 10.1080/17581966.2025.2477411

Rong Qiao, Xiajie Zhou, Wenli Li, Runbo Zhong, Jun Wang, Yakang Song, Jing Zhang, Tian Xu, Yue Wang, Liping Dai, Wanjian Gu, Baohui Han, Rongxi Yang

{"title":"The association between blood-based HYAL2 methylation and early-stage lung cancer: a case-control study.","authors":"Rong Qiao, Xiajie Zhou, Wenli Li, Runbo Zhong, Jun Wang, Yakang Song, Jing Zhang, Tian Xu, Yue Wang, Liping Dai, Wanjian Gu, Baohui Han, Rongxi Yang","doi":"10.1080/17581966.2025.2477411","DOIUrl":"10.1080/17581966.2025.2477411","url":null,"abstract":"Background: Blood-based DNA methylation biomarkers have great potential for the early detection of lung cancer (LC). Here, we investigated the association between HYAL2 methylation in peripheral blood and LC.Methods: Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was performed to measure the methylation levels of 4 CpG sites in HYAL2 gene in two independent case-control studies (168 LC cases and 167 controls in Study I, 677 LC cases and 833 controls in Study II). Logistic regression adjusted for covariates was conducted for odds ratios (ORs) and 95% confidence intervals (CIs). Non-parametric tests were applied for the comparisons of stratified groups.Results: Hypomethylation of all 4 CpG sites in HYAL2 was associated with early-stage LC in the two studies (ORs range from 1.91 to 3.07 in Study I, ORs range from 1.39 to 1.86 in Study II, p < 0.05 for all). The associations were still significant for the very early-stage LC patients (stage I). Subgroup analysis indicated that the associations could be enhanced by male gender and older age. Moreover, decreased HYAL2 methylation was correlated with increased tumor size, tumor length and stage.Conclusions: Our results suggested blood-based HYAL2 hypomethylation as a potential biomarker for LC early detection.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2477411"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC. 晚期 NSCLC 患者口服长春瑞滨单药的汇总分析。

IF 0.9

Lung Cancer Management Pub Date : 2025-12-01 Epub Date: 2025-03-21 DOI: 10.1080/17581966.2025.2477418

Christos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, Romain Raymond, Joaquim Bosch-Barrera

{"title":"Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.","authors":"Christos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, Romain Raymond, Joaquim Bosch-Barrera","doi":"10.1080/17581966.2025.2477418","DOIUrl":"10.1080/17581966.2025.2477418","url":null,"abstract":"Objectives: This was a pooled analysis of data from weekly vinorelbine (VNR) treatment arms of four individual open-label, phase II studies to assess and refine the efficacy and tolerance of weekly oral VNR in a larger cohort of patients with advanced NSCLC.Materials and methods: All patients included in this pooled analysis received oral VNR at the dose of 60 mg/m2 weekly at cycle 1 (3-week cycle), followed by an increase to 80 mg/m2 weekly for subsequent cycles until disease progression or toxicity. Efficacy was based on objective response rate (ORR), progression-free survival (PFS), and disease control rate (DCR).Results: A total of 247 patients were included. The ORR and DCR were 8.9% and 57.5% respectively, median PFS and OS were 3.3 and 8.5 months, respectively. Less than half (40.7%) of patients reported ≥1 serious AE (regardless of causality), with 12.3% reporting ≥1 treatment-related serious AE (grade ≥3: 11.1%). The most reported grade ≥3 AEs were neutropenia (17.6%), fatigue (5.8%), and decreased appetite (4.9%).Conclusion: This pooled analysis showed that weekly oral VRN is a valid option, with an acceptable safety profile, in this population of patients with advanced NSCLC, confirming results from previous individual studies.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2477418"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies. 交感神经系统功能增强会影响肺癌患者的预后：临床研究范围综述。

IF 0.9

Lung Cancer Management Pub Date : 2024-01-16 eCollection Date: 2023-12-01 DOI: 10.2217/lmt-2023-0006

Fabrício T Garramona, Telma F Cunha, Janaína S Vieira, Gabriela Borges, Gabriela Santos, Gilberto de Castro, Carlos Ugrinowitsch, Patrícia C Brum

引用次数: 0

Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC 联合检测 NSCLC 血浆 cfDNA 浓度和完整性的诊断价值

IF 2.8

Lung Cancer Management Pub Date : 2024-01-11 DOI: 10.2217/lmt-2023-0009

Sai Ren, Chunli Yu, Qing Huang

引用次数: 0

Bilateral synchronous multiple lung cancer: an emerging problem 双侧同步多发性肺癌：一个新出现的问题

IF 2.8

Lung Cancer Management Pub Date : 2023-12-19 DOI: 10.2217/lmt-2023-0008

Huajian Liu, Liam Polley

引用次数: 0

A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China 恩沙替尼治疗中国alk阳性局部晚期或转移性NSCLC患者的回顾性研究

Lung Cancer Management Pub Date : 2023-11-07 DOI: 10.2217/lmt-2023-0005

Xiaobin Yuan, Yang Wang, Min Yang, Pengxiang Wu, Hui Chen, Yu Yun, Zhilin Shen, Dong Ji, Yongbin Ma, Lieming Ding

引用次数: 0

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence. 早期非小细胞肺癌患者的生存和生活质量:现实世界证据的文献综述

IF 2.8

Lung Cancer Management Pub Date : 2023-09-01 DOI: 10.2217/lmt-2023-0003

Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin

{"title":"Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.","authors":"Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin","doi":"10.2217/lmt-2023-0003","DOIUrl":"https://doi.org/10.2217/lmt-2023-0003","url":null,"abstract":"Aim: Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients.Methods: Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies.Results: Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life.Conclusion: Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 3","pages":"LMT60"},"PeriodicalIF":2.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/bb/lmt-12-60.PMC10485735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis. 阿勒替尼治疗转移性alk阳性NSCLC:系统评价和网络荟萃分析。

IF 2.8

Lung Cancer Management Pub Date : 2023-06-01 DOI: 10.2217/lmt-2022-0018

Daniel Samacá-Samacá, Laura Prieto-Pinto, Andrés Yepes Peréz, Carolina Valderrama, Fabián Hernández

引用次数: 0

Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience. 非小细胞肺癌辅助化疗的真实结果和毒性:单中心研究。

IF 2.8

Lung Cancer Management Pub Date : 2023-03-01 DOI: 10.2217/lmt-2022-0014

Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins

{"title":"Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.","authors":"Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins","doi":"10.2217/lmt-2022-0014","DOIUrl":"https://doi.org/10.2217/lmt-2022-0014","url":null,"abstract":"Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.Methods: We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.Results: 62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.Conclusion: High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 1","pages":"LMT58"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing physician education to increase lung cancer screening uptake. 实施医师教育，提高肺癌筛查率。

IF 2.8

Lung Cancer Management Pub Date : 2023-02-01 DOI: 10.2217/lmt-2022-0008

Coral Olazagasti, Nagashree Seetharamu, Nina Kohn, David Steiger

{"title":"Implementing physician education to increase lung cancer screening uptake.","authors":"Coral Olazagasti, Nagashree Seetharamu, Nina Kohn, David Steiger","doi":"10.2217/lmt-2022-0008","DOIUrl":"https://doi.org/10.2217/lmt-2022-0008","url":null,"abstract":"Aim: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The US Preventive Services Task Force and National Comprehensive Cancer Network recommend annual low-dose computed tomography (LDCT) for eligible adults. We conducted a study to assess physician LDCT referral patterns.Methods: The study was divided into a pre-, intervention, and post-intervention periods. The intervention was a LC screening educational series. We evaluated rates of LDCT screening referrals during pre- and post-intervention periods.Results: In the pre-intervention period, 75 patients fulfilled US Preventive Services Task Force and/or National Comprehensive Cancer Network criteria and 27% underwent LDCT. In the post-intervention period, 135 patients fulfilled either screening criteria of whom 61.5% underwent LDCT.Conclusion: In our study, educational lectures improved compliance significantly and should be used as tool for primary care providers to effectively increase LDCT screening referrals.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"11 2","pages":"LMT55"},"PeriodicalIF":2.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/9c/lmt-11-55.PMC10135441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9392586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0